It was also reported that majority of the physicians agreed with the continuation of AFP until recovery from neutropenia and CR for AML/MDS patients (74.2%) and throughout the immunosuppressive period for GvHD patients after allogeneic HSCT (80.6%). The gene discussed is AFP; the disease is myelodysplastic syndrome.